New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2012
19:13 EDTLLYLilly ,Boehringe rpresent new linagliptin data
Boehringer Ingelheim Pharmaceuticals and Eli Lilly presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions. The new studies provide additional data evaluating the efficacy and safety of linagliptin (alone or in combination with other diabetes therapies) in adults with type 2 diabetes.[1],[2],[3] Linagliptin, marketed in the U.S. as Tradjenta, is a once-daily tablet that is used along with diet and exercise to improve glycemic control in adults with type 2 diabetes.[4] TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). TRADJENTA has not been studied in combination with insulin.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
09:20 EDTLLYARIAD drawing interest from companies besides Baxalta, dealReporter says
Subscribe for More Information
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use